Company intelligence / Profile preview
Cyclarity Therapeutics
Novato, California, United Statescyclaritytx.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Received regulatory approval to begin first-in-human clinical trial in January 2025. The trial will be conducted at CMAX in partnership with Monash University, led by Dr. Stephen Nicholls. The trial includes a traditional SAD/MAD phase 1 component plus enrollment of 12 patients with Acute Coronary Syndrome to assess safety and explore efficacy. All clinical trial material is manufactured and ready for administration, with all IND enabling studies completed successfully showing no predicted toxicological liabilities.
- Therapeutic areas
- OphthalmologyCardiovascularNeurology
- Modalities
- Custom-engineered cyclodextrins (polysaccharides)
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
CMAXMonash UniversityVictorian Heart Institute (VHI)
Beyond the preview
Go deeper on Cyclarity Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cyclarity Therapeutics.